Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 199.07

-3.4%

Nov 20 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John O'Neill who wrote (19370)	4/20/1998 12:01:00 PM
From: Henry Niman	Read Replies (3) of 32384

Speaking of LLY, I just caught the tail end of the CNBC interview with Vietor, Merrill Lynch's pharma analyst. He did note that although Evista started slowly for preventing osteoporosis, it's potential application for preventing breast cancer could turn it into a $ Billion drug fairly quickly. He mentioned the upcoming ASCO presentation and felt that the pharmas were expensive, but not necessarily out of line with the S&P 500. When asked for one drug company, he mentioned BMY, SGP, and "now LLY" and acknowledge that Merrill Lynch had buy recs on all three. (LLY set an all time high today)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next